UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2014
ALEXZA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-51820 | 77-0567768 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
Alexza Pharmaceuticals, Inc. 2091 Stierlin Court | 94043 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (650) 944-7000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 — Other Events
| Item 8.01. | Other Events. |
On July 31, 2014, Alexza Pharmaceuticals, Inc., a Delaware corporation, issued a press release announcing that (i) in the second half of 2014, it expects to initiate a Phase 2a study of AZ-002 (Staccato alprazolam) which is being developed for the management of patients with acute repetitive seizures and (ii) it has identified two newStaccato-based product candidates for development—AZ-008 and AZ-009—which will incorporate the active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza’s Staccato system. Alexza plans to develop AZ-008 for the acute treatment of restless legs syndrome and AZ-009 for hypomobility, or freezing, during “off periods” in Parkinson’s disease patients. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference
Section 9 — Financial Statements and Exhibits
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit Number | Description | |
| 99.1 | Press Release titled “Alexza Provides Pipeline Update” dated July 31, 2014. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALEXZA PHARMACEUTICALS, INC. | ||||||
| Date: July 31, 2014 | By: | /s/ Thomas B. King | ||||
| Thomas B. King | ||||||
| President and Chief Executive Officer | ||||||
INDEX TO EXHIBITS
Exhibit Number | Description | |
| 99.1 | Press Release titled “Alexza Provides Pipeline Update” dated July 31, 2014. | |